A

Argo Biopharma Tech Stack

Clinical-stage siRNA therapeutics developer advancing kidney and neurological therapies

Biotechnology Research Shanghai 51–200 employees Founded 2021 Privately Held

Argo Biopharma is a Shanghai-based siRNA drug developer with six candidates in clinical trials. The tech stack reveals a mature preclinical and manufacturing operation: RNAi/qPCR/LC-MS/MS for drug discovery and validation, HPLC/LC-MS for analytical work, and Oracle/MySQL for data systems — complemented by cloud infrastructure (GCP, Kubernetes) and modern development tools (Python, Cursor). Active hiring skews heavily toward research (70% of open roles), with senior-level positions dominating, signaling focus on advancing pipeline programs and building internal drug-discovery expertise rather than platform scaling.

Tech Stack 26 technologies

Core StackLinux Oracle MySQL SQL Server Python Java Kubernetes Nginx PostgreSQL Cursor GraphPad Prism SPSS Microsoft Office RNAi FlowJo LC-MS/MS HPLC qPCR Excel H3C Microsoft 365 Windows ITIL GCP LC-MS Claude

What Argo Biopharma Is Building

◆Challenges

Internal cost control
Reducing quality compliance risk
Building internal expertise
Expanding internal infrastructure
Therapeutic pipeline advancement
Early-stage drug discovery
Project timeline management
Financial reporting compliance
Developing synthetic routes
Low solubility of small nucleic acid drugs

▲Active Projects

Pns delivery platform
Drug discovery program for chronic kidney disease
Kidney-targeted delivery system design
Rna-targeted drug discovery program
Ind-enabling toxicology studies
Financial management system improvement
Peptide ligand screening
Aoc coupling process development
Process scale-up for gmp production
Process transfer to cdmo

Hiring Activity

Accelerating35 roles · 15 in 30d

Department

Research

24

Engineering

5

Manufacturing

3

Finance

1

Ops

1

Seniority

Senior

17

Mid

9

Principal

5

Director

2

Manager

1

Notable leadership hires: Finance Director

Company intelligence

Find more companies like Argo Biopharma by tech stack, pain points and active projects

Get started free

About Argo Biopharma

Argo Biopharma develops next-generation siRNA therapies targeting chronic kidney disease, neurological disorders, and other indications. Founded in 2021, the company operates as a clinical-stage biotech with in-house research, manufacturing, and quality capabilities across multiple geographies. The pipeline includes six therapeutic programs in clinical development, supported by active projects spanning kidney-targeted delivery systems, PNS (peripheral nervous system) delivery platforms, IND-enabling toxicology studies, and GMP manufacturing scale-up. Operational focus includes process optimization for CDMO partnerships and building synthetic routes to address solubility challenges inherent to small nucleic acid drugs.

HeadquartersShanghai

Company Size51–200 employees

Founded2021

Hiring MarketsChina

Frequently Asked Questions

What is Argo Biopharma's current pipeline?

Six therapeutic candidates are advancing in clinical trials targeting chronic kidney disease, neurological conditions, and other indications. Active projects include kidney-targeted delivery systems, PNS delivery platforms, and IND-enabling toxicology studies.

What drug discovery technologies does Argo Biopharma use?

RNAi, qPCR, LC-MS/MS, HPLC, FlowJo, and GraphPad Prism support preclinical and analytical work. Manufacturing and process development leverage GCP, Python, and Oracle/MySQL for data and operations.